We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

105 hedge funds and large institutions have $212M invested in Tetraphase Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 29 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 29

21% less call options, than puts

Call options by funds: $4.75M | Put options by funds: $6.01M

24% less funds holding

Funds holding: 139105 (-34)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

63% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 52

84% less capital invested

Capital invested by funds: $1.3B → $212M (-$1.09B)

Holders
105
Holders Change
-34
Holders Change %
-24.46%
% of All Funds
2.93%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
19
Increased
46
Reduced
29
Closed
52
Calls
$4.75M
Puts
$6.01M
Net Calls
-$1.26M
Net Calls Change
-$883K
Name Holding Trade Value Shares
Change
Change in
Stake
DekaBank Deutsche Girozentrale
76
DekaBank Deutsche Girozentrale
Germany
$137K +$33K +45 +5%
LWCFA
77
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$133K
California Public Employees Retirement System
78
California Public Employees Retirement System
California
$132K
VOYA Investment Management
79
VOYA Investment Management
Georgia
$130K -$15.3M -20,849 -96%
SGH
80
Schonfeld Group Holdings
New York
$121K +$595K +810 New
SEI Investments
81
SEI Investments
Pennsylvania
$109K +$253K +345 +89%
BG
82
BlackRock Group
United Kingdom
$104K +$252K +343 +97%
UBS AM
83
UBS AM
Illinois
$93K
ICM
84
ISZO Capital Management
New York
$90K +$440K +600 New
PPA
85
Parametric Portfolio Associates
Washington
$80K -$294K -400 -43%
TRCT
86
Tower Research Capital (TRC)
New York
$63K +$302K +411 +4,110%
BNP Paribas Financial Markets
87
BNP Paribas Financial Markets
France
$56.4K +$166K +226 +149%
MCM
88
Manchester Capital Management
Vermont
$56K
Legal & General Group
89
Legal & General Group
United Kingdom
$51K +$47.7K +65 +24%
Public Employees Retirement Association of Colorado
90
Public Employees Retirement Association of Colorado
Colorado
$39K
TDC
91
Thompson Davis & Co
Virginia
$29K
Teacher Retirement System of Texas
92
Teacher Retirement System of Texas
Texas
$26K +$89.5K +122 +222%
WA
93
WFG Advisors
Texas
$24K +$117K +160 New
LTFS
94
Ladenburg Thalmann Financial Services
Florida
$23K +$106K +145 +1,611%
RFC
95
Russell Frank Company
Washington
$14K -$1.51M -2,055 -96%
Canada Life
96
Canada Life
Manitoba, Canada
$14K
Citigroup
97
Citigroup
New York
$13K -$85.9K -117 -58%
PAM
98
Panagora Asset Management
Massachusetts
$13K +$2.2K +3 +3%
BlackRock
99
BlackRock
New York
$12K +$17.6K +24 +44%
CBT
100
Central Bank & Trust
Kentucky
$4K +$18.3K +25 New

TTPH Hedge Fund Activity: Q3 2015 in Review

105 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q3 2015, worth a combined $212M — down 84% from $1.3B a quarter earlier.

Sellers outnumbered buyers: 52 funds closed out of TTPH and 19 opened new positions — a net loss of 33 holders — while 29 trimmed existing stakes and 46 added.

The largest buyer was State Street, adding an estimated $84.5M. The largest seller was Jennison Associates, exiting entirely with an estimated $53.3M sold.

  • 105 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q3 2015, down from 139 in Q2 2015.
  • Funds reported $212M of Tetraphase Pharmaceuticals, Inc. stock for Q3 2015, down 84% quarter-over-quarter.
  • 19 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q3 2015 and 52 closed out, a net change of -33 holders.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q3 2015 was State Street, an estimated $84.5M added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q3 2015 was Jennison Associates, an estimated $53.3M sold.

Based on aggregated 13F filings for Q3 2015.